TY - JOUR
T1 - Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis
AU - Basso, Alexandre S.
AU - Frenkel, Dan
AU - Quintana, Francisco J.
AU - Costa-Pinto, Frederico A.
AU - Petrovic-Stojkovic, Sanja
AU - Puckett, Lindsay
AU - Monsonego, Alon
AU - Bar-Shir, Amnon
AU - Engel, Yoni
AU - Gozin, Michael
AU - Weiner, Howard L.
PY - 2008/4/1
Y1 - 2008/4/1
N2 - Axonal degeneration is an important determinant of progressive neurological disability in multiple sclerosis (MS). Thus, therapeutic approaches promoting neuroprotection could aid the treatment of progressive MS. Here, we used what we believe is a novel water-soluble fullerene derivative (ABS-75) attached to an NMDA receptor antagonist, which combines antioxidant and anti-excitotoxic properties, to block axonal damage and reduce disease progression in a chronic progressive EAE model. Fullerene ABS-75 treatment initiated after disease onset reduced the clinical progression of chronic EAE in NOD mice immunized with myelin-oligodendrocyte glycoprotein (MOG). Reduced disease progression in ABS-75-treated mice was associated with reduced axonal loss and demyelination in the spinal cord. Fullerene ABS-75 halted oxidative injury, CD11b+ infiltration, and CCL2 expression in the spinal cord of mice without interfering with antigen-specific T cell responses. In vitro, fullerene ABS-75 protected neurons from oxidative and glutamate-induced injury and restored glutamine synthetase and glutamate transporter expression in astrocytes under inflammatory insult. Glutamine synthetase expression was also increased in the white matter of fullerene ABS-75-treated animals. Our data demonstrate the neuroprotective effect of treatment with a fullerene compound combined with a NMDA receptor antagonist, which may be useful in the treatment of progressive MS and other neurodegenerative diseases.
AB - Axonal degeneration is an important determinant of progressive neurological disability in multiple sclerosis (MS). Thus, therapeutic approaches promoting neuroprotection could aid the treatment of progressive MS. Here, we used what we believe is a novel water-soluble fullerene derivative (ABS-75) attached to an NMDA receptor antagonist, which combines antioxidant and anti-excitotoxic properties, to block axonal damage and reduce disease progression in a chronic progressive EAE model. Fullerene ABS-75 treatment initiated after disease onset reduced the clinical progression of chronic EAE in NOD mice immunized with myelin-oligodendrocyte glycoprotein (MOG). Reduced disease progression in ABS-75-treated mice was associated with reduced axonal loss and demyelination in the spinal cord. Fullerene ABS-75 halted oxidative injury, CD11b+ infiltration, and CCL2 expression in the spinal cord of mice without interfering with antigen-specific T cell responses. In vitro, fullerene ABS-75 protected neurons from oxidative and glutamate-induced injury and restored glutamine synthetase and glutamate transporter expression in astrocytes under inflammatory insult. Glutamine synthetase expression was also increased in the white matter of fullerene ABS-75-treated animals. Our data demonstrate the neuroprotective effect of treatment with a fullerene compound combined with a NMDA receptor antagonist, which may be useful in the treatment of progressive MS and other neurodegenerative diseases.
UR - http://www.scopus.com/inward/record.url?scp=41849124231&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=41849124231&partnerID=8YFLogxK
U2 - 10.1172/JCI33464
DO - 10.1172/JCI33464
M3 - Article
C2 - 18340379
AN - SCOPUS:41849124231
SN - 0021-9738
VL - 118
SP - 1532
EP - 1543
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 4
ER -